3/26
05:03 am
imnn
IMNN: Updated OVATION 2 Data Shows 14.7-Month Improvement in OS Compared to SoC [Yahoo! Finance]
Medium
Report
IMNN: Updated OVATION 2 Data Shows 14.7-Month Improvement in OS Compared to SoC [Yahoo! Finance]
3/25
08:05 am
imnn
IMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer
Medium
Report
IMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer
3/24
08:00 am
imnn
IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026
Low
Report
IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026
2/5
08:05 am
imnn
IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY
Medium
Report
IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY
1/24
05:08 am
imnn
Imunon (NASDAQ:IMNN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Imunon (NASDAQ:IMNN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
1/7
05:01 pm
imnn
Imunon (NASDAQ:IMNN) had its "buy" rating reaffirmed by analysts at Brookline Capital Management.
Low
Report
Imunon (NASDAQ:IMNN) had its "buy" rating reaffirmed by analysts at Brookline Capital Management.
12/30
12:15 pm
imnn
IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules [Yahoo! Finance]
Low
Report
IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules [Yahoo! Finance]
12/30
08:30 am
imnn
IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules
High
Report
IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules
12/29
02:02 pm
imnn
IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL ADVANCES, LOOKING AHEAD TO 2026 [Yahoo! Finance]
Medium
Report
IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL ADVANCES, LOOKING AHEAD TO 2026 [Yahoo! Finance]
12/29
11:10 am
imnn
IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL ADVANCES, LOOKING AHEAD TO 2026
High
Report
IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL ADVANCES, LOOKING AHEAD TO 2026